LifeMine Therapeutics: Series D+Series EDevelops fungal genome-derived therapeutics for organ transplant rejectionOct 4, 2026RoundOSLifeMine TherapeuticsCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesHealthtechNorth AmericaUndisclosed